SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO )
CNTO 0.000010000.0%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thean who wrote (21)10/23/1996 5:56:00 PM
From: PawPr   of 965
 
I wouldn't be too concerned about the slow quarter for ReoPro sales:

1. Even interventional cardiologists take vacations. Summer is a slow time for all medical procedures.

2. In the current restrictive environment, insurers will only pay for drugs ( especially expensive ones like ReoPro ) which are used in accordance with specific FDA approved indications. The current indication for ReoPro is limited to high risk angioplasty. However, Centocor has performed studies to prove its usefulness in all angioplasties and in refractory angina. These results were so impressive that the FDA actually asked them to halt their controlled trials, in which some patients received an inactive placebo. When the FDA finally gets around to approving these two additional indications ( probably within the next six months ), which would significantly expand the market for the drug, sales should really take off. Obviously, the time to be in the stock is before this approval is granted, not after.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News